{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:13:53Z","timestamp":1793402033793,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.psychres.2025.116387","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T16:55:56Z","timestamp":1739206556000},"page":"116387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["A phase 2, placebo-controlled study to evaluate the efficacy and safety of BNC210, an alpha-7 nicotinic receptor negative allosteric modulator, for acute, as-needed treatment of social anxiety disorder (SAD) \u2013 The PREVAIL study"],"prefix":"10.1016","volume":"346","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3327-0352","authenticated-orcid":false,"given":"Spyros","family":"Papapetropoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8972-7315","authenticated-orcid":false,"given":"Elizabeth","family":"Doolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Odontiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9540-9455","authenticated-orcid":false,"given":"Dharam","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9564-2871","authenticated-orcid":false,"given":"Murray B.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.psychres.2025.116387_bib0001","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1600-0447.2008.01275.x","article-title":"Incidence of social phobia and identification of its risk indicators: a model for prevention","volume":"119","author":"Acarturk","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"issue":"3","key":"10.1016\/j.psychres.2025.116387_bib0002","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0887-6185(89)90009-1","article-title":"Assessment of social phobia: reliability of an impromptu speech task","volume":"3","author":"Beidel","year":"1989","journal-title":"J. Anxiety. Disord."},{"issue":"1","key":"10.1016\/j.psychres.2025.116387_bib0003","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0165-0327(99)00140-8","article-title":"Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment","volume":"60","author":"Brunello","year":"2000","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.psychres.2025.116387_bib0004","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.encep.2016.05.006","article-title":"Antid\u00e9presseurs et tol\u00e9rance : d\u00e9terminants et prise en charge des principaux effets ind\u00e9sirables [Antidepressant and tolerance: determinants and management of major side effects]","volume":"42","author":"David","year":"2016","journal-title":"Encephale"},{"key":"10.1016\/j.psychres.2025.116387_bib0005","first-page":"79","article-title":"Development of an improved oral tablet formulation of BNC210, a negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor, suitable for evaluation as an acute treatment for social anxiety disorder","volume":"47","author":"Doolin","year":"2022","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.psychres.2025.116387_bib0006","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3390\/neurolint13040059","article-title":"Benzodiazepines: uses, dangers, and clinical considerations","volume":"13","author":"Edinoff","year":"2021","journal-title":"Neurol. Int."},{"key":"10.1016\/j.psychres.2025.116387_bib0007","volume":"11","author":"Garakani","year":"2020","journal-title":"Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Front Psychiatry."},{"issue":"4","key":"10.1016\/j.psychres.2025.116387_bib0008","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1590\/S0100-879X2003000400003","article-title":"Pharmacology of human experimental anxiety","volume":"36","author":"Graeff","year":"2003","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"4","key":"10.1016\/j.psychres.2025.116387_bib0009","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/13543784.2023.2192922","article-title":"BNC210: an investigational \u03b17-nicotinic acetylcholine receptor modulator for the treatment of anxiety disorders","volume":"32","author":"Hampsey","year":"2023","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.psychres.2025.116387_bib0010","series-title":"American Society of Clinical Psychopharmacology Annual Meeting","article-title":"Efficacy and safety of an alpha 7 nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety in a randomized, placebo-controlled trial","author":"He","year":"2023"},{"key":"10.1016\/j.psychres.2025.116387_bib0011","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1037\/1064-1297.13.4.348","article-title":"Reinforcing effects of diazepam under anxiogenic conditions in individuals with social anxiety","volume":"13","author":"Helmus","year":"2005","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.psychres.2025.116387_bib0012","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1176\/appi.ps.201300201","article-title":"Employment barriers, skills, and aspirations among unemployed job seekers with and without social anxiety disorder","volume":"65","author":"Himle","year":"2014","journal-title":"Psychiatr. Serv."},{"issue":"3","key":"10.1016\/j.psychres.2025.116387_bib0013","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0005-7894(00)80027-1","article-title":"An instrument to assess self-statements during public speaking: scale development and preliminary psychometric properties","volume":"31","author":"Hofmann","year":"2000","journal-title":"Behav. Ther."},{"key":"10.1016\/j.psychres.2025.116387_bib0014","doi-asserted-by":"crossref","first-page":"S528","DOI":"10.1016\/S0924-977X(11)70859-8","article-title":"Pharmacodynamic effects of single doses of the novel anxiolytic compound BNC210 in healthy male volunteers","volume":"21","author":"Kremmidiotis","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2025.116387_bib0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0924-9338(00)00216-9","article-title":"A European perspective on social anxiety disorder","volume":"15","author":"Lecrubier","year":"2000","journal-title":"Eur. Psychiatry"},{"issue":"23","key":"10.1016\/j.psychres.2025.116387_bib0016","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMcp1614701","article-title":"Social Anxiety disorder","volume":"376","author":"Leichsenring","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.psychres.2025.116387_bib0017","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/(SICI)1520-6394(2000)11:3<87::AID-DA1>3.0.CO;2-9","article-title":"Why take social anxiety disorder seriously?","volume":"11","author":"L\u00e9pine","year":"2000","journal-title":"Depress. Anxiety."},{"key":"10.1016\/j.psychres.2025.116387_bib0018","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000414022","article-title":"Social phobia","volume":"22","author":"Liebowitz","year":"1987","journal-title":"Mod. Probl. PharmacoPsychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2025.116387_bib0019","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/appi.ajp.2014.12101342","article-title":"Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder","volume":"171","author":"Liebowitz","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116387_bib0020","series-title":"American Society of Clinical Psychopharmacology Annual Meeting","article-title":"(PH94B) Nasal spray for acute treatment of social anxiety disorder (SAD): results from the phase 3 PALISADE-2 trial","author":"Liebowitz","year":"2023"},{"issue":"6","key":"10.1016\/j.psychres.2025.116387_bib0021","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/npp.2015.316","article-title":"Multiple nicotinic acetylcholine receptor subtypes in the mouse amygdala regulate affective behaviors and response to social stress","volume":"41","author":"Mineur","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.psychres.2025.116387_bib0022","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/npr2.12275","article-title":"Antidepressants for social anxiety disorder: a systematic review and meta-analysis","volume":"42","author":"Mitsui","year":"2022","journal-title":"Neuropsychopharmacol. Rep."},{"issue":"1\u20132","key":"10.1016\/j.psychres.2025.116387_bib0023","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jad.2010.09.024","article-title":"Occupational impairment and Social Anxiety Disorder in a sample of primary care patients","volume":"130","author":"Moitra","year":"2011","journal-title":"J. Affect. Disord."},{"issue":"7426","key":"10.1016\/j.psychres.2025.116387_bib0024","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1136\/bmj.327.7426.1287-a","article-title":"Social anxiety disorder has social and economic burden","volume":"327","author":"Nardi","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.psychres.2025.116387_bib0025","unstructured":"National Institutes of Mental Health. Social Anxiety Disorder, 2023. Accessed October 5, 2024 at h t tps\/nimh.nih.gov."},{"key":"10.1016\/j.psychres.2025.116387_bib0026","series-title":"Abstract presented at the 2011 Neuroscience Conference","article-title":"The novel compound BNC210 partially reduces Panic Symptom Scale scores in a model of CCK-4 induced panic in healthy volunteers","author":"O'Connor","year":"2011"},{"key":"10.1016\/j.psychres.2025.116387_bib0027","series-title":"Neuroscience Conference","article-title":"The novel anxiolytic compound BNC210 is a negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor","author":"O'Connor","year":"2014"},{"issue":"Suppl 2","key":"10.1016\/j.psychres.2025.116387_bib0028","doi-asserted-by":"crossref","first-page":"S609","DOI":"10.1016\/S0924-977X(16)31690-X","article-title":"A multiple ascending dose study with evidence for target engagement of BNC210; a negative allosteric modulator of alpha7 nAChR in development for anxiety","volume":"26","author":"O'Connor","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2025.116387_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.109836","article-title":"BNC210, a negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor, demonstrates anxiolytic- and antidepressant-like effects in rodents","volume":"246","author":"O'Connor","year":"2024","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.psychres.2025.116387_bib0030","article-title":"Social media use, social anxiety, and loneliness: a systematic review","volume":"3","author":"O'Day","year":"2021","journal-title":"Comput Human Behav Reports"},{"key":"10.1016\/j.psychres.2025.116387_bib0031","first-page":"78","article-title":"Subjective Units of Distress Scale (SUDS) is a psychometrically valid and reliable outcome measure for the assessment of anxiety disorder (SAD) clinical trials","volume":"48","author":"Papapetropoulos","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2025.116387_bib0032","series-title":"Presented at the American Society of Clinical Psychopharmacology Annual Meeting","article-title":"Positive results achieved in a phase 2b, double-blind, placebo-controlled study for BNC210, an alpha7 nicotinic receptor negative allosteric modulator, for the treatment of PTSD (ATTUNE)","author":"Papapetropoulos","year":"2024"},{"issue":"2\u20133","key":"10.1016\/j.psychres.2025.116387_bib0033","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0165-0327(00)00323-2","article-title":"The economic consequences of social phobia","volume":"68","author":"Patel","year":"2002","journal-title":"J. Affect. Disord."},{"issue":"10277","key":"10.1016\/j.psychres.2025.116387_bib0034","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(21)00359-7","article-title":"Anxiety disorders","volume":"397","author":"Penninx","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.psychres.2025.116387_bib0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41398-020-01141-5","article-title":"Cholinergic modulation of disorder-relevant human defensive behaviour in generalised anxiety disorder","volume":"11","author":"Perkins","year":"2021","journal-title":"Transl. Psychiatry"},{"issue":"Pt B","key":"10.1016\/j.psychres.2025.116387_bib0036","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.neuropharm.2014.12.028","article-title":"Mood and anxiety regulation by nicotinic acetylcholine receptors: a potential pathway to modulate aggression and related behavioral states","volume":"96","author":"Picciotto","year":"2015","journal-title":"Neuropharmacology."},{"issue":"34","key":"10.1016\/j.psychres.2025.116387_bib0037","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1192\/S0007125000293458","article-title":"Health economics and cost implications of anxiety and other mental disorders in the United States","author":"Rice","year":"1998","journal-title":"Br. J. Psychiatry Suppl."},{"issue":"4","key":"10.1016\/j.psychres.2025.116387_bib0038","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/archpsyc.1992.01820040034004","article-title":"Weissman MM. Social phobia. Comorbidity and morbidity in an epidemiologic sample","volume":"49","author":"Schneier","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"issue":"8","key":"10.1016\/j.psychres.2025.116387_bib0039","first-page":"322","article-title":"Functional impairment in social phobia","volume":"55","author":"Schneier","year":"1994","journal-title":"J. Clin. Psychiatry"},{"issue":"7414","key":"10.1016\/j.psychres.2025.116387_bib0040","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/bmj.327.7414.515","article-title":"Social anxiety disorder","volume":"327","author":"Schneier","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.psychres.2025.116387_bib0041","series-title":"Manual For the State-Trait Anxiety Inventory: STAI (form Y)","author":"Spielberger","year":"1983"},{"issue":"11","key":"10.1016\/j.psychres.2025.116387_bib0042","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1586\/14737175.2014.963057","article-title":"The reappraisal of benzodiazepines in the treatment of anxiety and related disorders","volume":"14","author":"Starcevic","year":"2014","journal-title":"Expert. Rev. NeurOther"},{"issue":"2","key":"10.1016\/j.psychres.2025.116387_bib0043","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/0269881115612236","article-title":"Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis","volume":"30","author":"Steenen","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.psychres.2025.116387_bib0044","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1176\/appi.ajp.157.10.1606","article-title":"Disability and quality of life in social phobia: epidemiologic findings","volume":"157","author":"Stein","year":"2000","journal-title":"Am. J. Psychiatry"},{"issue":"9618","key":"10.1016\/j.psychres.2025.116387_bib0045","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(08)60488-2","article-title":"Social anxiety disorder","volume":"371","author":"Stein","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.psychres.2025.116387_bib0046","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12916-017-0889-2","article-title":"WHO World Mental Health Survey Collaborators. The cross-national epidemiology of social anxiety disorder: data from the World Mental Health Survey Initiative","volume":"15","author":"Stein","year":"2017","journal-title":"BMC. Med."},{"issue":"1","key":"10.1016\/j.psychres.2025.116387_bib0047","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1176\/ps.2009.60.1.61","article-title":"Impact of social anxiety disorder on employment among women receiving welfare benefits","volume":"60","author":"Tolman","year":"2009","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.psychres.2025.116387_bib0048","unstructured":"United States Food & Drug Administration. FDA requiring boxed warning updated to improve safe use of benzodiazepine drug class, 2020. Accessed October 5, 2024, h t tps\/fda.gov."},{"issue":"10","key":"10.1016\/j.psychres.2025.116387_bib0049","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.biopsych.2019.12.013","article-title":"Cholinergic modulation of disorder-relevant neural circuits in generalized anxiety disorder","volume":"87","author":"Wise","year":"2020","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2025.116387_bib0050","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0924-9338(00)00211-X","article-title":"Disability and quality of life in pure and comorbid social phobia. Findings from a controlled study","volume":"15","author":"Wittchen","year":"2000","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116387_bib0051","doi-asserted-by":"crossref","unstructured":"Wolpe J. Subjective units of distress scale. 1969. https:\/\/psycnet.apa.org\/doi\/10.1037\/t05183-000.","DOI":"10.1037\/t05183-000"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178125000368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178125000368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T18:43:46Z","timestamp":1742755426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178125000368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":51,"alternative-id":["S0165178125000368"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2025.116387","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2, placebo-controlled study to evaluate the efficacy and safety of BNC210, an alpha-7 nicotinic receptor negative allosteric modulator, for acute, as-needed treatment of social anxiety disorder (SAD) \u2013 The PREVAIL study","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2025.116387","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116387"}}